On November 16, ASCO published the Systemic Therapy for Advanced Hepatocellular Carcinoma Guideline. Atezolizumab bevacizumab (atezo bev) may be offered as first-line treatment of most patients with advanced HCC, Child-Pugh class A liver disease, Eastern Cooperative Oncology Group Perfor-mance Status (ECOG PS) 0-1, and following management of esophageal varices, when present, according to institutional guidelines. Slides, a recommendations table, patient information, visual abstract, and algorithm accompany the guideline.

Please visit Apple Podcasts and Google Play for highlights on key recommendations from the publication.